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AbstrACt
Objectives To assess the value for money of 
unicompartmental knee replacement (UKR) compared with 
total knee replacement (TKR).
Design A lifetime Markov model provided the framework 
for the analysis.
setting Data from the National Joint Registry (NJR) for 
England and Wales primarily informed the analysis.
Participants Propensity score matched patients in the 
NJR who received either a UKR or TKR.
Interventions UKR is a less invasive alternative to TKR, 
where only the compartment affected by osteoarthritis is 
replaced.
Primary outcome measures Incremental quality-
adjusted life years (QALYs) and healthcare system costs.
results The provision of UKR is expected to lead to a 
gain in QALYs compared with TKR for all age and gender 
subgroups (male: <60 years: 0.12, 60–75 years: 0.20, 
75+ years: 0.19; female: <60 years: 0.10, 60–75 years: 
0.28, 75+ years: 0.44) and a reduction in costs (male: 
<60: £−1223, 60–75 years: £−1355, 75+ years: £−2005; 
female: <60 years: £−601, 60–75 years: £−935, 75+ 
years: £−1102 per patient over the lifetime). UKR is 
expected to lead to a reduction in QALYs compared with 
TKR when performed by surgeons with low UKR utilisation 
but an increase among those with high utilisation (<10%, 
median 6%: −0.04, ≥10%, median 27%: 0.26). Regardless 
of surgeon usage, costs associated with UKR are expected 
to be lower than those of TKR (<10%: £−127, ≥10%: 
£−758).
Conclusions UKR can be expected to generate better 
health outcomes and lower lifetime costs than TKR. 
Surgeon usage of UKR does, however, have a significant 
impact on the cost-effectiveness of the procedure. To 
achieve the best results, surgeons need to perform a 
sufficient proportion of knee replacements as UKR. Low 
usage surgeons may therefore need to broaden their 
indications for UKR.
IntrODuCtIOn
For individuals with end-stage symptom-
atic osteoarthritis of the knee, total knee 
replacement (TKR) relieves pain and 
improves function.1 A substantial propor-
tion of patients, by some estimates up to 
50%,2 could receive a unicompartmental 
knee replacement (UKR) instead. UKR is less 
invasive than TKR, sparing the normal joint 
surfaces and cruciate ligaments3 4 and conse-
quently is associated with a faster recovery 
and lower risk of postoperative complications 
and mortality.5 6 In early and late compari-
sons of patient-reported outcome measures 
(PROMs), UKR has also been shown to 
result in superior outcomes, with a higher 
proportion of patients reporting an excel-
lent result.7 8 However, UKR is also associated 
with a higher risk of revision than TKR,5 with 
this due in large part to a lower threshold for 
revision.9 
The choice between UKR and TKR also 
has economic implications. Given that typical 
length of stay is lower for UKR,5 undertaking 
a UKR can be expected to require fewer 
healthcare system resources than a TKR. This 
upfront cost-saving could, however, be offset 
by the cost of additional reoperations and 
revisions. Differences in outcomes, in terms 
strengths and limitations of this study
 ► Routinely collected data provided real-world evi-
dence of costs and health outcomes following uni-
compartmental knee replacement (UKR) and total 
knee replacement (TKR).
 ► Propensity score matching was used to identify 
comparable individuals who received UKR or TKR.
 ► Differences between comparator groups may have 
remained in unobserved characteristics, such as 
preoperative radiographs.
 ► Assumptions were required to extrapolate quality of 
life and risk of revision over patient lifetimes.
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of pain and function, may also lead to differences in 
primary healthcare utilisation, which would further affect 
the overall costs of the procedures.
The relative merit of each procedure can be expected 
to vary depending on patient and surgical factors. 
Outcomes following UKR, in particular, are impacted 
by surgical factors. Surgeons’ caseload (the number of 
UKR performed) and usage of UKR (the percentage of 
their primary knee replacements that are UKRs) have 
been shown to have a substantial impact on the success 
of UKR with those performed by high usage surgeons 
expected to have comparable reoperation rates with 
TKR.10
Cost-effectiveness analyses offer a means of reducing 
decision uncertainty by providing a comparative anal-
ysis of both the costs and health outcomes of UKR 
and TKR. Our aim in this study was to estimate the 
cost-effectiveness of UKR compared with TKR based on 
routinely collected data from the UK and, in particular, 
to assess how cost-effectiveness varies depending on (1) 
the age and gender of patients and (2) surgeon usage 
of UKR.
MAterIAls AnD MethODs
target population and subgroups
The study population for this analysis is comprised of 
those patients who could receive either a UKR or TKR. We 
use propensity score matching to identify those patients 
who received a TKR who were similar to patients who 
received a UKR in all relevant observable characteristics 
and assume both groups to be eligible for a UKR but ulti-
mately receiving either a TKR or a UKR. We consider the 
cost-effectiveness of UKR compared with TKR in terms of 
six subgroups based on age (<60 years, 60–75 years and 
>75 years) and gender. In a further analysis, we consider 
the effect of surgeon ‘usage’ of UKR on cost-effectiveness 
for two subgroups (<10% and ≥10%).
Decision model
A lifetime Markov model, shown in figure 1, provides the 
framework for the analysis, with patients passing through 
clinically and economically important health states as 
time passes.11 Patients begin by having a primary UKR or 
TKR, after which they have a revision operation or remain 
unrevised. After a revision, patients can have a further 
revision (re-revised) or remain revised. Following a re-re-
vision, patients remain as re-revised until death. From all 
health states, patients have a risk of death, and the model 
goes through consecutive cycles until all patients have 
died. Patients can transition between states on a yearly 
basis. The key simplifying assumptions of the model are 
that patients can have only two revisions and that only 
one revision can occur in a year. While reoperations are 
not incorporated as a model state, their likelihood and 
costs are incorporated into the unrevised state.
study perspective
This evaluation has been undertaken from a healthcare 
system perspective, hence only the costs incurred by the 
health system are included. These costs relate to surgical 
procedures being undertaken and primary care utilisation 
by patients. For healthcare interventions to be considered 
cost-effective (ie, providing sufficient value for money to 
merit their provision) in England, they should have an 
incremental cost per additional quality-adjusted life year 
(QALY) of less than £20 000–£30 000.12 For this analysis, 
the cost-effectiveness of UKR is considered at the lower 
threshold of £20 000.
Measurement of effectiveness
An extract of data from the National Joint Registry (NJR) 
for England and Wales linked to the Hospital Episode 
Statistics database and the Office for National Statistics 
informed estimates of the effectiveness of UKR and TKR. 
These data were previously used to compare adverse 
events following the procedures, with propensity scores 
used to match 25 334 UKRs to 75 996 comparable TKRs 
who received their primary procedure between 2003 and 
2012.10 These same matched patients were split into the 
age and gender subgroups for this analysis. As surgeon 
usage of UKR was not a variable in the original propensity 
score matching, matching was rerun to achieve balance 
within usage subgroups (see online supplementary 
appendix). This ensured that the comparator groups, 
UKR performed by surgeons with usage under 10% 
against TKR, and UKR by surgeons with usage equal to or 
over 10% against TKR, were balanced in their observable 
characteristics.
Parametric models were specified independently for 
each treatment subgroup to estimate the risk of revi-
sion and death. For the base case analysis, the Weibull 
distribution was used for both. The risk of revision was 
extrapolated using estimates from the models, and risk 
of death was assumed to return to that given by age-spe-
cific and gender-specific UK life tables after the period 
of follow-up.13 Sensitivity analyses were performed for the 
Figure 1 Model outline. The decision analytic model 
provides the framework for the analysis. TKR, total knee 
replacement; UKR, unicompartmental knee replacement.
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risk of revision with the analysis rerun using the log-normal 
and exponential distributions instead of the Weibull. 
Further details of the estimated parametric models are 
provided in the online supplementary appendix.
Risk of re-revision was based on evidence from the 
NJR, which reported that in the first year following a 
revision, patients have a 2.7% probability of a re-revision 
and a 1.4% chance in subsequent years.14 With risk of 
re-revision being similar following a revision of UKR and 
TKR,15 these risks were applied in the same manner for 
both procedures. Risk of mortality following a revision 
and re-revision was assumed to be equal to that of those 
unrevised.
estimating resource use and costs
The hospital costs associated with the primary proce-
dures and revisions were based on patients’ Healthcare 
Resource Group codes (which classify episodes with 
similar levels of resource consumption into the same 
group) and length of stay, with costs estimated using the 
2014/2015 National Tariff Payment System.16 In addi-
tion, the costs of any implant-retaining reoperations over 
the five years following each surgery were also incorpo-
rated. We assumed the cost of a re-revision was the same 
as a revision in the base case analysis. The effect of this 
assumption on the results was tested by rerunning the 
analysis with a re-revision expected to have a cost 50% 
higher than that of a revision.
For primary care costs an extract of the Clinical Prac-
tice Research Datalink was used where 335 UKRs were 
matched with 1005 TKRs based on propensity scores. 
These patients and their costs are summarised in the 
online supplementary appendix. The choice of proce-
dure was found to have no significant effect on resource 
use and so the costs of treatment groups were pooled, and 
single estimates were extracted for each age and gender 
subgroup.
Future costs and health outcomes were discounted by 
an annual rate of 3.5%, in line with guidelines for England 
and Wales.17 Costs are in British pounds, in 2014 prices. 
Estimated hospital and primary care costs are detailed in 
the online supplementary appendix.
Measurement and valuation of preference-based outcomes
As PROMs have only been collected for patients under-
going knee replacements in the English NHS since 
2009, a separate propensity score matched cohort of 
3519 UKRs and 10 557 TKRs for whom these data were 
available were used to inform estimates of health-related 
quality of life for each subgroup considered. Again, these 
patients and the process of matching have been previ-
ously described in detail,7 and matching was rerun for 
usage subgroups (see online supplementary appendix). 
EuroQol-5D (EQ-5D) is a generic measure of health-re-
lated quality of life, whose preference-based scores for 
England range from −0.59 (worst) to 1 (best), with 0 
representing death and 0.074 considered a minimally 
important difference.18
In the year following a primary, patients were expected 
to steadily progress from their preoperative score to their 
postoperative score at six months, at which they would 
remain for the rest of that year. As EQ-5D following UKR 
and TKR has been shown to remain stable over 10 years 
following surgery for unrevised patients,8 in the absence 
of any further procedure, those unrevised were expected 
to remain at their postoperative score. The trajectory of 
quality of life following revision was assumed to be similar 
to primary procedures, with patients expected to prog-
ress from their preoperative score to their postoperative 
score over six months, at which point they were expected 
to remain unless they went on to have a re-revision. 
However, due to the small number of individuals with a 
revision and scores available, subgroups were pooled for 
revision parameters. We assumed quality of life for a re-re-
vision would fall by the same proportion as it did from 
primary to a revision procedure. To test the impact of 
this assumption, we conducted a sensitivity analysis where 
the quality of life for a re-revision was assumed instead to 
remain equal to that of revision. Estimates of health-re-
lated quality-of-life were based on EQ-5D collected prior 
to and six months following surgery (see online supple-
mentary appendix).
Analytic methods
Expected (mean) costs and QALYs were estimated 
for each subgroup receiving either UKR or TKR. The 
resulting incremental cost-effectiveness ratio (ICER) 
was then calculated (equal to the difference in costs 
divided by the difference in QALYs), with an intervention 
being considered dominant if it both reduced costs and 
increased QALYs.19 The effect of parameter uncertainty 
was assessed using probabilistic sensitivity analysis, with 
input parameters assigned from probability distributions 
and 1000 Monte Carlo simulations conducted for each 
subgroup. Probability distributions were based on the 
type of data, with gamma distributions used for costs as 
well as preoperative quality of life so as to allow values 
below zero, beta distributions used for postoperative 
quality of life and normal distributions used for the coef-
ficients of parametric models and age.20 21 The sets of esti-
mated costs and QALYs from each of 1000 Monte Carlo 
simulations are presented, alongside the expected results, 
on a cost-effectiveness plane.
Patient and public involvement
No patients were involved in the development of the 
research question or the outcome measures nor the 
design of the study. There are no plans to disseminate the 
results of the research to study participants.
results
Compared with TKR, UKR was found to be associated 
with a greater likelihood of revision over individuals 
remaining lifetimes for each of the subgroups. UKR was, 
however, associated with better postoperative quality 
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of life following the primary procedure than TKR for 
all age and gender subgroups, with the difference most 
pronounced for older patients. Moreover, those under-
going revision following UKR had better quality of life 
prior to and following revision than those who had TKR. 
For all subgroups, the hospital costs of primary and revi-
sion surgery were lower for UKR than TKR. See online 
supplementary appendix for further details.
UKR was found to be cost-saving and health improving 
compared with TKR for all age and gender subgroups, 
making UKR the dominant treatment choice for those 
individuals eligible for either procedure (see table 1). 
The largest expected savings were for males over 75 
years, while the biggest improvement in quality of life 
was for females over 75 years. For those aged over 60 
years of age, parameter uncertainty had little effect on 
the conclusion that UKR was cost-effective. However, 
for those under 60 years, there was some uncertainty, 
with a 13% and 28% probability that TKR was cost-effec-
tive for males and females under 60 years, respectively. 
Table 1 Base case cost-effectiveness results for age and gender subgroups
TKR UKR
∆ QALYs ∆ Costs (£)
ICER 
(probability 
UKR cost-
effective*)QALYs Costs (£) QALYs Costs (£)
Male,
<60 
years
10.28
(10.07 to 10.47) 
15 357 
(14 704 to 16 019) 
10.39
(10.11 to 10.70) 
14 134
(13 489 to 14 810) 
0.12
(− 0.19 to 0.47) 
−1223
(−1439 to − 1014) 
UKR dominant 
(87%)
Male,
60–75 
years
8.61
(8.50 to 8.70) 
13 307
(12 584 to 14 037) 
8.81
(8.63 to 8.97) 
11 952
(11 246 to 12 704) 
0.20
(0.01 to 0.39) 
−1355
(− 1610 to − 1122) 
UKR dominant 
(100%)
Male,
75+ 
years
5.61
(5.49 to 5.73) 
11 454
(10 506 to 12 511) 
5.80
(5.64 to 5.97) 
9450
(8442 to 10 631) 
0.19
(0.02 to 0.37) 
−2005
(−2361 to −1521) 
UKR dominant 
(100%)
Female,
<60 
years
10.68
(10.50 to 10.89) 
16 961
(16 101 to 17 899) 
10.78
(10.42 to 11.09) 
16 360
(15 514 to 17 273) 
0.10
(− 0.33 to 0.47) 
−601
(− 887 to −350) 
UKR dominant 
(72%)
Female,
60–75 
years
8.96
(8.84 to 9.06) 
13 814
(13 089 to 14 602) 
9.24
(9.04 to 9.43) 
12 878
(12 068 to 13 702) 
0.28
(0.05 to 0.50) 
−935
(−1186 to − 710) 
UKR dominant 
(100%)
Female,
75+ 
years
6.02
(5.82 to 6.15) 
11 410
(10 541 to 12 378) 
6.46
(6.20 to 6.69) 
10 308
(9312 to 11 378) 
0.44
(0.18 to 0.71) 
−1102
(−1646 to −695) 
UKR dominant 
(100%)
Expected (mean) values with 95% CIs in parentheses. UKR is considered ‘dominant’ if it is expected to improve health outcomes and reduce 
healthcare costs.
*Given a cost-effectiveness threshold of £20 000.
ICER, incremental cost-effectiveness ratio; QALYs, quality-adjusted life years; TKR, total knee replacement; UKR, unicompartmental knee 
replacement. 
Figure 2 Cost-effectiveness plane for age and gender subgroups. The sets of estimated incremental costs and QALYs 
associated with the provision of UKR rather than TKR from each of the Monte Carlo simulations are shown as points with the 
expected results as triangles. QALYs, quality-adjusted life years; TKR, total knee replacement; UKR, unicompartmental knee 
replacement.
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Figure 2 presents the estimated mean and probabilistic 
sets of incremental costs and QALYs associated with the 
provision of UKR rather than TKR for each age and 
gender subgroup. These findings were broadly robust 
to changes in modelling assumptions (see table 2 and 
online supplementary appendix for full results from 
each scenario analysis).
When UKR was performed by surgeons with a usage 
of the procedure equal to or above 10% (median 
usage was 27%), UKR was found to be unequivocally 
cost-saving and health improving compared with TKR, 
as shown in table 3. When performed by surgeons 
with usage of less than 10% (median usage was 6%), 
however, UKR was no longer expected to lead to better 
health outcomes than TKR, and TKR became the more 
likely cost-effective procedure. Figure 3 presents the 
estimated means and sets of costs and QALYs for both 
usage subgroups.
DIsCussIOn
Principal findings
For patients who are eligible for either procedure, the 
provision of UKR rather than TKR has been estimated 
to lead to a gain in QALYs and a reduction in costs for 
all age and gender subgroups. There is little uncertainty 
around this conclusion for older patients. Such patients 
have, given their lower life expectancy, a lower lifetime 
risk of revision and report greater improvements in post-
operative quality of life compared with TKR than younger 
Table 2 Scenario analyses
Age and gender subgroups
Male, 75+ years
Female, <60 
years
Female, 60–75 
years
Female, 75+ 
yearsMale, <60 years
Male, 60–75 
years
Base case 
assumptions
UKR dominant UKR dominant UKR dominant UKR dominant UKR dominant UKR dominant
(87%) (100%) (100%) (72%) (100%) (100%)
Distribution of parametric model for revision risk
  Exponential UKR dominant UKR dominant UKR dominant UKR dominant UKR dominant UKR dominant
(92%) (100%) (100%) (78%) (100%) (100%)
  Log-normal UKR dominant UKR dominant UKR dominant UKR dominant UKR dominant UKR dominant
(89%) (100%) (100%) (77%) (100%) (100%)
Health utility
  Re-revision 
equal to 
revision
UKR dominant UKR dominant UKR dominant UKR dominant UKR dominant UKR dominant
(95%) (100%) (100%) (91%) (100%) (100%)
Cost
  Cost of re-
revision 50% 
higher than 
revision
UKR dominant UKR dominant UKR dominant UKR dominant UKR dominant UKR dominant
(83%) (100%) (100%) (73%) (100%) (100%)
Incremental cost-effectiveness ratio (ICER) with probability of UKR being cost-effective, based on probabilistic sensitivity analysis and given 
a cost-effectiveness threshold of £20 000, in parentheses. UKR is considered ‘dominant’ if it is expected to improve health outcomes and 
reduce healthcare costs. Full results for each scenario analysis are detailed in the online supplementary appendix.
UKR, unicompartmental knee replacement.
Table 3 Base case cost-effectiveness results for usage of UKR subgroups
TKR UKR
∆ QALYs ∆ Costs (£)
ICER 
(probability UKR 
cost-effective*)QALYs Costs (£) QALYs Costs (£)
UKR <10% 8.67
(8.53 to 8.80) 
13 267
(12 834 to 13 731) 
8.62
(8.38 to 8.84) 
13 140
(12 643 to 13 614) 
−0.04
(−0.32 to 0.21) 
−127
(−429 to 127) 
£3000/QALY 
(37%)
UKR ≥10% 8.81
(8.73 to 8.88) 
13 170
(12 726 to 13 614) 
9.06
(8.94 to 9.18) 
12 411
(11 978 to 12 856) 
0.26
(0.12 to 0.40) 
−758
(−939 to −579) 
UKR dominant 
(100%)
Expected (mean) values with 95% CIs in parentheses. UKR is considered ‘dominant’ if it is expected to improve health outcomes and reduce 
healthcare costs.
*Given a cost-effectiveness threshold of £20 000.
ICER, incremental cost-effectiveness ratio; QALYs, quality-adjusted life years; TKR, total knee replacement; UKR, unicompartmental knee 
replacement. 
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patients. Significant uncertainty does surround whether 
UKR would be health improving for younger patients for 
whom even relatively small differences in annual revision 
rates lead to substantial differences in lifetime revision 
rates.
Surgeon usage of UKR, that is, the percentage of the 
knee replacements they perform that were UKRs, had 
a significant impact on the cost-effectiveness of the 
procedure. UKR was expected to be cost-effective when 
compared with TKR with 100% probability (given param-
eter uncertainty) when performed by surgeons with usage 
at or above 10%, with these surgeons having a median 
usage of 27%. However, when UKR performed by low 
usage surgeons were compared against TKR, TKR was the 
more likely cost-effective option.
limitations of the study
Our analysis was based on routinely collected data from 
the National Health Service in England and Wales. While 
this dataset has the advantage of providing real-world 
evidence for costs and health outcomes following UKR 
and TKR, it also has the potential pitfalls of any such 
observational data. In particular, confounding by indi-
cation can be expected with treatment selection based 
on patient and surgical characteristics. Propensity score 
matching was used to achieve balance in a wide range of 
observed characteristics; however, imbalances may still 
exist in unobserved factors that could bias the findings 
of the study. In particular, it was not possible to include 
preoperative radiographs, which would provide a better 
assessment of patients eligible to have either procedure; 
hence, differences in these may have persisted between 
matched groups.
With costs and health outcomes estimated over the 
remaining lifetimes of patients, modelling assumptions 
were unavoidable. Individuals’ risk of revision over their 
remaining lifetimes were based on observed revisions 
over the eight years following surgery. In addition, quality 
of life estimates were based on scores recorded prior to 
and six months following primary and revision proce-
dures, and we assumed that, in the absence of further 
procedures, individuals would remain at their postop-
erative scores into the future. This assumption appears 
to be plausible following primary procedures8; however, 
it is uncertain whether a similar pattern would be seen 
following revisions. If quality of life following revision 
steadily returned to comparable levels observed after 
primary procedures, the cost-effectiveness of UKR, which 
has a higher risk of revision, will have been somewhat 
underestimated. Furthermore, we assumed quality of 
life associated with re-revision would have dropped by 
the same proportion as that observed from primary to 
revision and the cost of a re-revision was assumed to be 
equivalent to that of a revision. These assumptions were 
necessarily subjective; however, scenario analyses showed 
the findings of the study to be robust to changes in these 
assumptions.
study findings in context
In line with findings from previous economic evaluations 
of UKR and TKR,22 in this study, we found UKR to be less 
costly than TKR. Furthermore, consistent with previous 
research, UKR was also found to lead to better health 
outcomes for patients aged 65 years and over. Little 
uncertainty surrounds this conclusion for older patients, 
who benefit most from a less invasive procedure and have 
a low lifetime risk of revision. For younger patients, whose 
health outcomes are mixed,23–25 this analysis found that 
UKR was also expected to lead to better health outcomes 
than TKR, although there was significant uncertainty in 
this conclusion. The variation in findings for younger 
patients across studies appears to be driven by differences 
in estimates for both the risk of revision and the expected 
effect of revision on quality of life.
This study has also highlighted the importance of 
surgeon usage of UKR on the cost-effectiveness of the 
Figure 3 Cost-effectiveness plane for usage subgroups. The sets of estimated incremental costs and QALYs associated with 
the provision of UKR rather than TKR from each of the Monte Carlo simulations are shown as points with the expected results 
as triangles. QALYs, quality-adjusted life year; TKR, total knee replacement; UKR, unicompartmental knee replacement. 
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procedure. In the high usage group, with a median usage 
of 27%, UKR was found, with no parameter uncertainly, 
to lead to better health outcomes and to cost-savings 
compared with TKR. In contrast, in the low usage group, 
UKR led to expected worse health outcomes and only 
small cost savings. High-usage surgeons appear to achieve 
good results following UKR regardless of their caseload of 
the procedure, and so the poor results of those with low 
usage appear to be primarily due to inappropriate patient 
selection.26 In particular, low-usage surgeons seem more 
likely to offer UKR to patients with partial-thickness carti-
lage loss (PTCL). PTCL is associated with poor outcomes 
following UKR and so it has been recommended that 
UKR should only be undertaken for individuals with 
bone-on-bone arthritis.10 High-usage surgeons, therefore, 
should be supported, while low-usage surgeons should 
consider changing their practice. If surgeons with low or 
no usage of UKR learnt and applied the indications and 
techniques of current high-usage surgeons, they can be 
expected to achieve similar results.
COnClusIOns
For those patients with appropriate indications, UKR 
provides an alternative to TKR that is less costly for the 
healthcare system to provide and leads to better health 
outcomes over their lifetime. If surgeons performing 
UKR achieved sufficient usage of the procedure, future 
economic and population health gains would likely be 
increased even further. Additional work is needed to 
identify the optimal usage of UKR, which may depend on 
the type of implants used. Surgeons should not have a low 
usage and be performing UKR in less than 10% of their 
knee replacements. The median usage in the high usage 
group was 27%, so it would be reasonable for surgeons to 
aim for a quarter of their knee replacements to be UKR. 
However, it has been shown that up to 50% of replace-
ments could be UKR, so the optimal usage may be higher.
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